MicroRNA‑23a/24‑2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta‑analysis

  • Authors:
    • Jing Quan
    • Suyue Liu
    • Kangfu Dai
    • Lu Jin
    • Tao He
    • Xiang Pan
    • Yongqing Lai
  • View Affiliations

  • Published online on: November 8, 2017     https://doi.org/10.3892/mco.2017.1492
  • Pages: 159-169
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

An increasing number of studies have proven that microRNAs play an important role in the occurrence, development and prognosis of various types of cancer. As a vital gene cluster, the microRNA (miR)‑23a/24‑2/27a cluster may be an important marker for predicting cancer prognosis and tumor progression. A search was conducted through PubMed, Medline and the Cochrane Library to identify studies investigating the association between the miR‑23a/24‑2/27a cluster and cancer, and the identified related studies were included in the present meta‑analysis. The strength of the association was assessed by hazard ratio (HR) and its 95% confidence interval (95% CI). A total of 21 studies were included in this meta‑analysis. The results indicated that a high level of miR‑23a exerted a significant effect on overall survival (OS) (HR=2.33, 95% CI: 1.18‑4.58; P=0.014), but not on disease‑free survival (DFS)/recurrence‑free survival (RFS) (HR=1.13, 95% CI: 0.37‑3.44; P=0.836). There was an obvious statistically significant association between OS and the expression of miR‑24 (HR=2.49, 95% CI: 1.84‑3.37; P=0.000), particularly in the digestive system (pooled HR=2.99, 95% CI: 2.17‑4.13, P=0.000). In addition, the result suggested a statistically significant association between the expression of miR‑27a and OS (pooled HR=1.89, 95% CI: 1.32‑2.69; P=0.001), as well as DFS/RFS/progression‑free survival (HR=2.19, 95% CI: 1.29‑3.70; P=0.003), particularly in renal cell carcinoma (HR=2.30, 95% CI: 1.16‑4.67; P=0.017). A subgroup analysis by ethnicity, cancer type and statistical methodology was performed. There was no obvious publication bias. In conclusion, the present study demonstrated that the miR‑23a/24‑2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Quan J, Liu S, Dai K, Jin L, He T, Pan X and Lai Y: MicroRNA‑23a/24‑2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta‑analysis. Mol Clin Oncol 8: 159-169, 2018
APA
Quan, J., Liu, S., Dai, K., Jin, L., He, T., Pan, X., & Lai, Y. (2018). MicroRNA‑23a/24‑2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta‑analysis. Molecular and Clinical Oncology, 8, 159-169. https://doi.org/10.3892/mco.2017.1492
MLA
Quan, J., Liu, S., Dai, K., Jin, L., He, T., Pan, X., Lai, Y."MicroRNA‑23a/24‑2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 8.1 (2018): 159-169.
Chicago
Quan, J., Liu, S., Dai, K., Jin, L., He, T., Pan, X., Lai, Y."MicroRNA‑23a/24‑2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 8, no. 1 (2018): 159-169. https://doi.org/10.3892/mco.2017.1492